(Q37953297)

25 August 2017

title

FRAX(®) with and without bone mineral density (English)

1 reference

25 August 2017

5

1 reference

25 August 2017

2

Eugene McCloskey

1 reference

25 August 2017

4

Anders Oden

1 reference

25 August 2017

1

John A Kanis

1 reference

25 August 2017

3

Helena Johansson

1 reference

25 August 2017

language of work or name

English

0 references

publication date

6 November 2011

1 reference

Calcified Tissue International

25 August 2017

published in

1 reference

25 August 2017

volume

90

1 reference

25 August 2017

issue

1

1 reference

25 August 2017

page(s)

1-13

1 reference

https://scigraph.springernature.com/pub.10.1007/s00223-011-9544-7

25 August 2017

exact match

0 references

cites work

FRAX and the assessment of fracture probability in men and women from the UK

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

The incidence and risk of hip fracture in Poland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

FRAX and its applications to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Health economics of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

FRAX and its applications in health economics--cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Effects of risedronate on fracture risk in postmenopausal women with osteopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

A revised clinician's guide to the prevention and treatment of osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

BMD, clinical risk factors and their combination for hip fracture prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

The US FRAX filter: avoiding confusion or hindering progress?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

International variations in hip fracture probabilities: implications for risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9544-7

10.1007/S00223-011-9544-7

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference